This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic. NIAID does NOT offer the primary screening of previously untested products via this service. Products must be single-component entities of known chemical structure; evaluation of multi-component natural product extracts is not supported.
Assays that can be provided include:
Additional tasks that can be provided under this service include:
The current contractor for this service is Southern Research Institute, Frederick Maryland.
NIAID’s point of contact for this service is Dr. Steven Turk.
back to top
Last Updated July 07, 2009